HCV Inhibitors
Viriome's First Novel Mechanism Drug Candidates
•Class I new chemical entities
–Inhibit an early step downstream of entry but before replication
–Lead optimization by “click chemistry” 10nM against infection with >2500x less cytotoxicity against normal cells
•Group A compounds
•
Known target without known association to HCV
•
Additional compounds of lower priority at different points in lifecycle
•
Screening for new mechanism inhibitors continues